Experimental combo for MDS and AML shows early promise but trial halted
NCT ID NCT05275439
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tested an experimental drug called SL-172154, given alongside standard chemotherapy drugs, for people with higher-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goals were to check safety and find the right dose. The study was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SL-172154 (a fusion protein) combined with azacitidine or azacitidine and venetoclax
- What this could lead to
- If successful, this could point toward a new combination treatment for certain blood cancers like MDS and AML.
- What could go wrong
- This is a very early (Phase 1) trial that was terminated, so results are limited. The approach may not prove safe or effective in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor Scott & White Research Institute
Dallas, Texas, 75246, United States
-
City of Hope
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
King's College Hospital NHS Foundation Trust
London, Denmark Hill, SE5 9RS, United Kingdom
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40202, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2C1, Canada
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The University of Chicago
Chicago, Illinois, 60637, United States
-
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2, Canada
-
UCLA Medical Center-Bowyer Oncology Center
Los Angeles, California, 90095, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University Hospitals Plymouth NHS Trust, Derriford Hospital
Crownhill, Plymouth, PL6 8DH, United Kingdom
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of North Carolina, Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
VCU Massey Cancer Center
Richmond, Virginia, 23219, United States
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?